Ureterolithotripsy under Spinal Anesthesia in Pompe Disease (Glycogen Storage Disease Type 2): A Case Report

Arzu Acar, Mustafa Nuri Denız, Elvan Erhan, Gulden Ugur

Department of Anaesthesiology and Reanimation, School of Medicine, Ege University, Izmir, Turkey..

DOI: 10.4236/ojanes.2013.32016                

Abstract

Pompe disease is an autosomal recessive inherited glycogen storage disease, usually respiratory muscles, cardiac muscle and skeletal muscles are affected in childhood and mortality is inevitable but has a slower progression in the adult. The patient was a 35-year-old male patient who was scheduled to undergo ureterorenoscopy due to right ureteral stone. He was diagnosed with pompe disease after detection of myopathy on EMG due to muscle weakness in the legs and hips. He was started on myozyme vials once every 15 days. Spinal anesthesia with 3 ml 0.5% hyperbaric bupivacaine was performed and adequate sensorial and motor block was achieves at T₁₀ level. The surgery was completed with no complications and he was discharged two days later. The selection of appropriate anesthetic technique and a careful perioperative and postoperative monitoring are of utmost importance due to progressive muscle weakness, hypotonia, respiratory failure and cardiomyopathy in pompe disease.

Keywords

Pompe Disease; Spinal Anesthesia; Ureterorenoscopie

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. Sakakibara, Y. Teramoto, T. Aoyama, T. Takahashi, M. Hara, M. Maseki and S. Yamaguchi, “A Case Report of Anesthesia for a Child with Pompe’s Disease (Glycogen Storage Disease Type II),” Masui, Vol. 58, No. 2, 2009, pp. 219-222.
[2]	T. Fukuda, A. Roberts, P. H. Plotz and N. Raben, “Acid Alphaglucosidase Deficiency (Pompe Disease),” Current Neurology and Neuroscience Reports, Vol. 7, No. 1, 2007, pp. 71-77. doi:10.1007/s11910-007-0024-4
[3]	Z. Illés and A. Trauninger, “Pompe’s Disease. Part I: Pathogenesis and Clinical Features,” Ideggyogyaszati Szemle, Vol. 62, No. 6-7, 2009, pp. 231-243.
[4]	B. Schoser, V. Hill and N. Raben, “Therapeutic Approaches in Glycogen Storage Disease Type II/Pompe Disease,” Neurotherapeutics, Vol. 5, No. 4, 2008 pp. 569-578. doi:10.1016/j.nurt.2008.08.009
[5]	P. Laforêt, M. Nicolino and B. Eymard, “New Approaches for the Treatment of Metabolic Myopathies,” Revue Neurologique, Vol. 163, No. 10, 2007, pp. 930-935. doi:10.1016/S0035-3787(07)92636-3
[6]	A. Amallfitano, A. R. Bengur, R. P. Morse, et al., “Recombinant Human Acid a Glucosidase Enzyme Therapy for Infantile Glycogen Storage Disease Type II: Results of Phase I/II Clinical Trial,” Genetics in Medicine, Vol. 3, No. 2, 2001, pp. 132-138.
[7]	P. S. Kishnani, R. D. Steiner, D. Bali, et al., “Pompe Disease Diagnosis and Management Guideline,” Genetics in Medicine, Vol. 8, No. 5, 2006, pp. 267-288. doi:10.1097/01.gim.0000218152.87434.f3
[8]	L. Y. Wang, A. K. Ross, J. S. Li and S. M. Dearmey, “Cardiac Arrhythmias Following Anesthesia Induction in Infantile-Onset Pompe Disease: A Case Series,” Pediatric Anesthesia, Vol. 17, No. 8, 2007, pp. 738-748. doi:10.1111/j.1460-9592.2007.02215.x
[9]	R. W. Walker, G. Briggs, J. Bruce, J. Fletcher and E. D. Wraith, “Regional Anesthetic Techniques Are an Alternative to General Anesthesia for Infants with Pompe’s Disease,” Pediatric Anesthesia, Vol. 17, No. 7, 2007, pp. 697-702. doi:10.1111/j.1460-9592.2007.02196.x
[10]	H. J. Cilliers, S. T. Yeo and N. P. Salmon, “Anaesthetic Management of an Obstetric Patient with Pompe Disease,” International Journal of Obstetric Anesthesia, Vol. 17, No. 2, 2008, pp. 170-173. doi:10.1016/j.ijoa.2007.11.001